相关实验视频

Updated: Jun 4, 2025

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

对局部晚期结肠癌患者的新辅助疗法的叙述性综述

Jen-Pin Chuang^1,2,3, Yen-Chen Chen^4,5,6, Jaw-Yuan Wang^4,5,6,7,8

¹Chiayi Hospital, Ministry of Health and Welfare, Chiayi, Taiwan.

The Kaohsiung journal of medical sciences

|December 24, 2024

概括

局部晚期结肠癌 (LACC) 管理正在发展. 化学疗法,化学放射疗法和免疫疗法等新辅助疗法可以改善LACC患者的外科治疗结果和生存率.

科学领域:

在瘤学瘤学.
手术瘤学手术瘤学
胃肠病学胃肠病学

背景情况:

结肠直肠癌是全球主要的健康挑战,局部晚期结肠癌 (LACC) 存在显著的生存困难.
由于LACC的特点是T4入侵或广泛的节点参与,因此需要采用多学科的方法,目前的标准是彻底手术和辅助化疗.
在LACC中实现完整的瘤切除 (R0) 往往是困难的,因为瘤透到相邻结构.

研究的目的:

审查局部晚期结肠癌 (LACC) 的不断发展的治疗策略.
突出新辅助疗法在改善手术切除率和患者存活率方面的作用.
强调基于瘤生物标志物和反应的个性化治疗的重要性.

主要方法:

对LACC的新辅助化疗 (NACT),新辅助化疗 (NACRT) 和新辅助免疫疗法 (NAIT) 的当前文献的综述.
对临床试验数据的分析 (例如,FOxTROT,PRODIGE 22,NICHE-2,NICHE-3) 评估新辅助干预措施.
讨论治疗选择的预测生物标志物 (例如,MMR状态,T阶段).

主要成果:

NACT,特别是FOLFOX或CAPOX,已显示出在瘤下降阶段,增强存活率和增加R0切除率方面的有效性.
NACRT显示了瘤回归的希望,在LACC管理中具有潜在的应用.
特别是在不匹配修复缺陷 (dMMR) 瘤中,NAIT显示出高的病理反应率.

结论:

将新辅助疗法整合到LACC管理中可以显著改善手术和生存结果.
以瘤特征和对新辅助干预的反应为指导的个性化治疗策略,对于优化患者护理至关重要.
进一步的研究和临床试验至关重要,以完善和扩大对LACC的这些先进治疗方法的使用.

关键词:

在本地发达的结肠癌.不匹配的维修维修不匹配的维修新辅助性化疗或放射治疗.新辅助性化疗是一种新辅助性化疗.新辅助免疫疗法新辅助免疫疗法

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Endoscopic Procedures II: Colonoscopy

Endoscopic Procedures II: Colonoscopy

The colon, or large intestine, is the final segment of the digestive system. Its primary functions include absorbing water and vitamins produced by gut bacteria and transforming waste from liquid to solid to form stool. In adults, the large intestine is approximately 5 feet long and consists of four main sections: